In November 2024, AstraZeneca launched Breztri Aerosphere, a fixed-dose combination inhaler designed for effective COPD management. The inhaler, which combines budesonide and formoterol fumarate in one device, is now available in several international markets. This innovation aims to enhance patient adherence and improve outcomes in COPD management, providing long-lasting relief and improved lung function.
